Richard D Anna, MD
Urology · Little Rock, ARNPI 1578538963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Endo Pharmaceuticals Inc. at 34.2% of the total. Reporting peaked in 2019 at $385 and has fallen 62.6% since, to $144 in 2023. That places this record below the midpoint for urology clinicians in AR, where the typical reported total is $5,249.
Across 30 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$198
- Johnson & Johnson$111
- Astellas Pharma US Inc$63
- AbbVie$56
- Axonics, Inc.$55
- Dendreon Pharmaceuticals LLC$45
- plus $50 from 3 others
Across 176 payments — averaging $4191.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$203K
- AbbVie$184K
- Ferring Pharmaceuticals AS$154K
- Myriad Genetic Laboratories, Inc.$99K
- Ferring International Pharmascience Center US$67K
- Urotronic, Inc$16K
- plus $14K from 2 others
What the payments were for
- Food & beverage$579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 2 | $198 |
| Johnson & Johnson | 12 | $111 |
| Astellas Pharma US Inc | 4 | $63 |
| AbbVie(2 entities) | 4 | $56 |
| Axonics, Inc. | 2 | $55 |
| Dendreon Pharmaceuticals LLC | 3 | $45 |
| Tolmar, Inc. | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$113
How this compares
$579 in reported general payments places this provider in the 20th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 52 | $2,883 |
| Tamsulosin Hcl | 46 | $715 |
| Dutasteride | 12 | $420 |
| Anastrozole | 49 | $136 |
Paid to pharmacies, not to this prescriber.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- John MooreLittle Rock$19K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.